Anell Anders, Persson Ulf
Swedish Institute for Health Economics, Lund, Sweden.
Eur J Health Econ. 2005 Sep;6(3):274-9. doi: 10.1007/s10198-005-0301-6.
Introduction of the new Pharmaceutical Benefits Board (LFN; 1 October 2002) has markedly changed the principles of pricing and reimbursement of drugs in Sweden. The Board is required to make decisions based on information on cost-effectiveness, and pharmaceutical companies must submit economic evaluations when relevant as part of their applications for reimbursement. This study examined experience to date regarding the use of health-economic evaluations and cost-effectiveness information by the LFN. We also describe activities and the use of cost-effectiveness analysis by Swedish local formulary committees organized by the 21 county councils. It is concluded that economic evaluations have supported decision making by LFN, although cost-effectiveness seems to be of varying importance in different situations. While the use of health-economic evaluations and the outcome of decision making by LFN are similar to comparable committees in other countries, there is presently a gap in this sense between the LFN and Swedish local formulary committees. Coordinated decision making is much needed but may be difficult to implement as the perspective, expertise, and objectives of the two public authorities differ.
新的药品福利委员会（LFN；2002年10月1日）的引入显著改变了瑞典药品定价和报销的原则。该委员会必须根据成本效益信息做出决策，制药公司在相关情况下必须提交经济评估报告，作为其报销申请的一部分。本研究考察了迄今为止LFN在使用健康经济评估和成本效益信息方面的经验。我们还描述了由21个郡议会组织的瑞典地方处方委员会的活动以及成本效益分析的使用情况。得出的结论是，经济评估为LFN的决策提供了支持，尽管成本效益在不同情况下的重要性似乎有所不同。虽然LFN使用健康经济评估的情况以及决策结果与其他国家类似委员会的情况相似，但目前LFN与瑞典地方处方委员会在这方面存在差距。协调决策非常必要，但由于两个公共机构的视角、专业知识和目标不同，可能难以实施。
